Bandhan Core Equity mutual fund has seen pick-up in performance; should you stay invested?
mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.
BASIC FACTS
DATE OF LAUNCH
9 AUGUST 2005
CATEGORY
EQUITY
TYPE
LARGE & MIDCAP
AUM*
Rs.2,802 crore
BENCHMARK
NIFTY LARGE MIDCAP 250 TOTAL RETURN INDEX
WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.85.90
IDCW**
Rs.21.69
MINIMUM INVESTMENT
Rs.1,000
MINIMUM SIP AMOUNT
Rs.100
EXPENSE RATIO* (%)
1.99
EXIT LOAD
For units in excess of 10% of the investment,1% will be charged for redemption within 365 days.
#AS ON 31 JULY 2023
*AS ON 31 JULY 2023
**AS ON 29 AUGUST 2023
FUND MANAGER
MANISH GUNWANI
6 MONTHS
Recent portfolio changes
New entrants
Ajanta Pharma, Apar Industries, Asahi India Glass, Aurobindo Pharma, Crompton Greaves Consumer Electricals, GE T&D India, Gland Pharma, Hindalco Inds, Hitachi Energy India, Indian Bank, Jio Financial Services, KEC International, Macrotech Developers, M&M Financial Services, Navin Fluorine International, NHPC, Polycab India, REC, Siemens, Sona BLW Precision Forgings, The Federal Bank, Vishnu Chemicals.
Complete exits
Aditya Birla Capital, Cholamandalam Investment & Finance Company, Container Corporation of India, Emami, Equitas Small Finance Bank, Housing Development Finance Corporation, IndusInd Bank, K.P.R.
Mill, Kalpataru Projects International, Natco Pharma, Supreme Industries.
Should you buy?
Earlier run with a fluid approach under IDFC Classic Equity, this fund now keeps a balance between large and mid caps under its new mandate. The fund preference is for quality businesses —generating cash flow, superior return on capital and ability to repay debt—with a bias towards lower relative valuation in its sector.
